Immuron Submits Investigational New Drug Application for Clostridioides Difficile Infection Treatment Candidate to the US FDA
MT Newswires Live
Oct 08
Immuron (ASX:IMC) submitted an investigational new drug application to the US Food and Drug Administration (FDA) for the clinical development of IMM-529 to treat Clostridioides difficile infection and prevent recurrent infection, according to a Wednesday Australian bourse filing.
It plans to initiate a second-phase clinical trial for the treatment candidate in individuals with Clostridioides difficile infection during the first half of 2026. The clinical trial is expected to enroll both first-episode and recurrent infection patients.
The firm's shares rose over 1% in recent trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.